W ith their ability to home in on precise targets while ignoring everything else, monoclonal antibodies are powerful ...

In the present work, van der Schoot et al. genetically engineered hybridomas using one-step CRISPR/homology-directed repair. They rapidly generated the recombinant hybridomas to secrete mAbs in the Fc ...

The increase in the utilization of monoclonal antibodies as therapeutics over the past two decades has been remarkable, with over 80 mAbs approved for use. The quick pace of clinical studies and ...

The development of early monoclonal antibody (mAb) therapies centered around the hybridoma platform requires the production of target antigen or immunogen and animal immunizations. This means there ...